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A serendipitous pharmacogenetic finding links the vulnerability to developing levodopa-induced dyskinesia to the age of onset of
Huntington’s disease. Huntington’s disease is caused by a polyglutamate expansion of the protein huntingtin. Aberrant huntingtin
is less capable of binding to a member of membrane-associated guanylate kinase family (MAGUKs): postsynaptic density- (PSD-)
95. This leaves more PSD-95 available to stabilize NR2B subunit carrying NMDA receptors in the synaptic membrane. This results
in increased excitotoxicity for which particularly striatal medium spiny neurons from the indirect extrapyramidal pathway are
sensitive. In Parkinson’s disease the sensitivity for excitotoxicity is related to increased oxidative stress due to genetically determined
abnormal metabolism of dopamine or related products. This probably also increases the sensitivity of medium spiny neurons for
exogenous levodopa. Particularly the combination of increased oxidative stress due to aberrant dopamine metabolism, increased
vulnerability to NMDA induced excitotoxicity, and the particular sensitivity of indirect pathway medium spiny neurons for this
excitotoxicity may explain the observed increased prevalence of levodopa-induced dyskinesia.
1. Introduction
Over 45 years after discovery of its beneficial effects [1, 2],
levodopa remains the mainstay of treatment of Parkinson’s
disease (PD). Usage of levodopa for treatment of motor
symptoms at all stages of PD is supported by strong evi-
dence [3]. However, long-term levodopa treatment of PD is
frequently complicated by motor fluctuations and dyskinesia
[3–6]. Monotherapy with dopamine agonists in the early
phases of the disease reduces the risk of dyskinesia compared
with levodopa, but dopamine agonists are unable to prevent
dyskinesia once levodopa is added, which is always required
once disease severity progresses [7]. Until now, no effective
drug treatment of levodopa-induced dyskinesia (LID) has
been developed [8]. Several theories try to explain the
pathophysiology of this important treatment complication
with the ultimate goal of developing such treatments [8–10].
However, the exact pathological mechanism has also not yet
been elucidated.
Recently, our group has published our serendipitous
finding in a small group of patients we used as a control
group in a study on tardive dyskinesia (TD) [11, 12]. Our
analysis revealed that two GRIN2A variants, rs7192557 and
rs8057394, were most frequently associated with dyskinesia
in our control group of patients with neurological disorders
(101 with Parkinson’s disease, 21 with essential tremor, and 21
with different forms of dystonia). It is important to notice that
rs7192557 is a tagging SNP for rs1969060, which was previ-
ously associated with the age of onset in Huntington’s disease,
and that SNP rs8057394 was the other variant identified in
this study of Arning et al. [13]. In our study we found that
rs7192557 and rs8057394 were not significantly associated
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with tardive dyskinesia in 431 patients with schizophrenia
[11].
Huntington’s disease (HD) is an inherited neurodegen-
erative disorder, characterized by progressively worsening
chorea, cognitive and psychiatric disturbances involving the
basal ganglia and cerebral cortex [14]. HD is caused by a
mutation of the gene of huntingtin protein (htt), located in the
4p16.3 region of the short arm of chromosome 4, showing an
increased number of CAG nucleotides [15]. The involuntary
movement disorder in HD [16] is similar to that of LID [4],
although in both cases symptomatology is highly variable and
inHD dependent on disease stage. In HD, the disease process
has been linked to NMDA receptor-induced excitotoxicity in
the striatal medium-sized spiny neurons (MSNs) that form
the indirect pathway [14, 15, 17].
In the current paper we try to examine a possible simi-
larity between the pathological mechanisms of LID and HD
based on the found association of two GRIN2A variants and
the progression of both diseases. We start with a description




The GRIN2A gene encodes for a protein which is part of the
ionotropic glutamatergic N-methyl-D-aspartate (NMDA)
receptor [18]. The amino acid L-glutamate is an excitatory
neurotransmitter in the central nervous system,mediating its
effects via ionotropic and metabotropic receptors. Ionotropic
receptors are ligand-gated channels and divided into three
groups, one of which is the group of NMDA receptors.
These NMDA receptors consist of four (or five) proteins
belonging to three different types: NR1, NR2, or NR3. At
least one NR1 subunit is present in the NMDA receptor. This
NR1 subunit combines with at least one modulatory NR2
subunit and more infrequently a modulatory NR3 subunit.
Four different NR2 subunits have been identified: NR2A,
NR2B, NR2C, and NR2D. Together, these complexes form
membrane-bound, nonselective cation channels character-
ized by voltage-dependent activity, high calcium permeabil-
ity, and comparatively slow activation/deactivation kinetics
[18].
NR2A and NR2B are relatively large proteins with molec-
ular masses of about 170–180 kDa.They have a large extracel-
lular N-terminal region, which carries a glutamate binding
site, three relatively small transmembrane domains (M1, M3,
and M4), and a small reentry loop (M2), which is critical
for Ca2+ permeability and Mg2+ sensitivity [18]. NMDA
receptors are anchored within the postsynaptic surface mem-
brane by binding through their C-terminal region to synap-
tic proteins associated with the membrane cytoskeleton.
An example is the binding of NR2A and NR2B subunits
to members of the membrane-associated guanylate kinase
family (MAGUKs): postsynaptic density- (PSD-) 95/synapse
associated protein- (SAP-) 90 [19]. Binding to MAGUKs
links NMDA receptors to other membrane proteins on one
hand and to important intracellular signaling proteins on
the other [20]. Binding to MAGUKs also plays an important
role in trafficking NMDA receptors between synaptic and
extrasynaptic (intracellular) localization [20, 21]. Changing
these signaling and trafficking activities may play a role in
NMDA associated excitotoxicity in HD. Sun et al. provided
evidence that normal huntingtin is associatedwithN-methyl-
D-aspartate (NMDA) receptors via postsynaptic density-95
(PSD-95) and that polyglutamine expansion interferes with
the ability of huntingtin to interact with PSD-95 [22]. Fan et
al. provided direct evidence that polyglutamate expansion of
huntingtin increases the interaction betweenNR2B and PSD-
95 [23]. This results in increased NMDA receptor activity as
is, for example, reflected by the evoked current amplitude
and caspase-3 activity, an enzyme playing a central role in
regulating neuronal death in theCNS [24].This effect appears
to be selective for NMDA receptors carrying NR2B subunits,
as NR2A-NMDA receptors showed similar sensitivity when
coexpressed with mutant versus normal huntingtin [25].
In spite of this selectivity of huntingtin protein for affect-
ing neurotoxicity of NR2B carrying NMDA receptors, also
NR2A subunits have been associated with modulation of this
neurotoxicity. However, the results are not entirely consistent.
Arning et al. described that in a cohort of 167 HD patients a
significant part of the variance of age of onset of illness could
be attributed to aGRIN2B (rs1806201) and to a lesser extent to
a GRIN2A (rs1969060) variant [26]. These authors later fine-
mapped a larger HD sample (𝑁 = 250) and showed that two
additional SNPs (rs8057394 and rs2650427) showed an even
stronger association than the originally identified GRIN2A
variant [13]. Andresen et al. tried to confirm these results in
443 subjects who were heterozygotes for the HD gene (only
one allele with >35 CAG repeats) and had been diagnosed
with Huntington’s disease [27]. In this Venezuelan sample
again evidence was found of association of the GRIN2A SNP
(rs1969060), but not of the GRIN2B variant. In a European
cohort of 1,069 HD patients the analysis did not, however,
replicate the association between the SNP rs1969060 and the
age of onset [28]. However, in 241 patients initially presenting
psychiatric symptoms rs1969060 polymorphisms explained
a considerable amount of variance in residual age of onset.
TheGRIN2ASNP rs2650427 showed a significant association
with the age of onset of symptoms in all 1,069 patients. Ramos
et al. studied 1,619 HD patients and found no evidence for
a significant association between GRIN2A SNP rs2650427
polymorphisms and the age of onset ofmotor symptoms [29].
This type of differences is not very surprising. Variations
of the GRIN2A genotype probably only determine the vul-
nerability to developingHD symptoms to aminor degree and
there may exist several factors which contribute to a similar
degree. The heterozygosity may vary greatly between various
patient populations. As amatter of fact, the C allele frequency
of the GRIN2A C/T SNP (rs2650427) is 17% in Europe
and 52–56% in Asia and Africa [27]. Moreover, especially
in large patients cohorts, the results of association studies
may be flawed by poor phenotyping and the contribution
of numerous, not accounted for, confounders. In addition,
both SNPs rs1969060 and rs2650427 are positioned in intron
parts of theGRIN2A gene on chromosome 16 [13].Therefore,
























Figure 1: The cortico-striatal-thalamic-cortical circuits, including
the indirect and direct pathways; ENK = enkephalin; GPe = globus
pallidus, external segment; GPi = globus pallidus, internal segment;
SNc = substantia nigra, pars compacta; SNr = substantia nigra, pars
reticulata; SP/DYN = substance P/dynorphin; STh = subthalamic
nucleus; D1 or D2: medium-sized spiny neurons with D1 or D2
receptors.
function. However, the found associations support the idea
that modification of the efficacy of NR2A containing NMDA
receptors may have consequences for the likelihood of the
excitotoxicity promoted by HD related changes in huntingtin
protein.
Glutamate is the most ubiquitous excitatory neurotrans-
mitter in the nervous system, but in HD indirect pathway
medium spiny neurons are primarily affected (Figure 1).
This can be explained by looking at the distribution of
NMDA receptor subunits. Although NR1 is widely dis-
tributed throughout most neurons in the brain, each of the
NR2 subunits shows a more discrete distribution. NR2A
and NR2B are highly expressed in most neurons of the
cerebral cortex, hippocampus, and thalamus, whereas NR2C
is mainly expressed in the cerebellum (where NR2A, but not
NR2B, may also be found) and NR2D in the brainstem and
spinal cord [30, 31]. NR2B subunits have been shown to be
more extensively expressed relative to NR2A in the rodent
striatum [31, 32]. This is used to explain the vulnerability of
striatal medium spiny neurons to polyglutamate huntingtin
[32]. We are not aware of experiments showing differences
of the distribution of NR2A and NR2B subunits between
MSNs of the direct and indirect pathway. However, striatal
neuronal subtypes are selectively protected by neurotrophic
factors against excitotoxic insults [33].ThismakesMSNof the




The mechanism of levodopa-induced dyskinesia is usually
studied in animal models in which nigrostriatal dopamin-
ergic neurons have been lesioned with 1-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine (MPTP) or 6-hydroxydopamine
(6-OHDA) [4, 8, 34]. In our opinion these models have a
serious limitation, namely, that these animals do not suffer
from genuine PD. In PD the degeneration of nigrostriatal
dopaminergic neurons has to be attributed to genetically
determined metabolic alterations which increase the neuro-
toxicity of dopamine and/or metabolites. These alterations
occur within dopaminergic neurons during the initial disease
process, but it is very unlikely that exogenous levodopa will
be processed differently. Therefore, patients with genuine PD
must be far more vulnerable to these effects than MPTP-
or 6-OHDA-lesioned animals. Therefore, animal models can
better be considered to indicate how levodopa acutely induces
dyskinesia within nigrostriatal dopamine-deficient animals
instead of models for the pathophysiological mechanism
of LID. Dopamine can be considered to be a particularly
neurotoxic endogenous substance. Dopamine metabolism
results in releasing hydrogen peroxide, which results in the
production of free radicals, which then cause cell damage
[35]. This damage is limited by the influence of certain
enzymes, like manganese superoxide dismutase (MnSOD),
which scavenge these free radicals. This neurotoxicity is
potentiated by a high level of activation of NMDA receptors,
which also increases oxidative stress by finally activating
nitric oxide synthase (nNOS) [18].
We want to hypothesize that the pathological basis of LID
might be degeneration of indirect pathway medium spiny
neurons.This could best be studied by comparing the striatal
neuronal composition of patients with PD with and without
dyskinesia and that of normal controls. Unfortunately, we did
not find such comparisons described in the literature. Calon
et al. found increased binding to NR1/NR2B and AMPA
glutamate receptors in the lateral putamen associated with
the clinical observation of LD-induced motor complications
in advanced PD, but this tells relatively little about their
subcellular localization and the mechanism behind it [36].
When our hypothesis is accepted, why the clinical presen-
tation of LID is so variable becomes better understandable.
The pattern of dyskinesia varies with respect to the time of
onset in relation to levodopa intake [8]. This might result
from instability of the systemdue to preferential degeneration
of indirect pathway MSN in comparison to GABAergic
projection neurons of the direct pathway. A classical theory
of the mechanism of LID tells that, due to the degenera-
tion of dopaminergic terminals, the “buffering capacity” of
presynaptic uptake has disappeared [8]. Therefore, exoge-
nous levodopa results in pulsatile under- and overstimula-
tion of dopaminergic receptors [4, 8]. Chronic intermittent
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Figure 2: Simplified representation of the corticostriatal processing
unit in which cortical information leading to a movement is
processed in an intracortical and (parallel) extrapyramidal fashion;
(A) sensory input, (B) projections to brainstem and spinal cord,
and (C) projection to and from ipsilateral and contralateral cortical
areas. NS = nonspecific part; S = specific part.
stimulation of normally tonically active dopaminergic D1
receptors brings about alterations in cell signals in corti-
costriatal and thalamostriatal glutamatergic synapses. This
causes long-term potentiation of these excitatory glutamater-
gic efferents, particularly, resulting in overstimulation of
direct pathway medium spiny neurons [4]. However, we
want to emphasize that these changes will have a far larger
impact when the regulatory system is already unstable. It
should be kept in mind that the extrapyramidal circuit is a
sophisticated regulatory system which controls the output
of frontal cortical areas by converging direct and indirect
pathways coming from and connecting several other cortical
domains (Figures 1 and 2) [12]. Most activation patterns are
learned during training the execution of specific movement
complexes. This process is probably more easily disturbed
by adverse long-term potentiation of corticostriatal and
thalamostriatal synapses when the integrity of the system
itself is compromised.
Why would a change within the functioning of NMDA
receptors carrying NR2A subunits result in increased vul-
nerability to develop LID, as we have found in our Siberian
PD patients [11]? This was not a tiny effect. For example,
the odds ratio for an association between rs7192557 (tagging
rs1969060) and LID was 3.21 (95% CI: 1.37–7.51, 𝑝 = 0.0062)
for 101 patients diagnosed with Parkinson’s disease and 2.71
(95% CI: 1.35–5.46, 𝑝 = 0.0046) for the whole group
of 143 patients with neurological disorders. For rs8057394,
these figures were 3.59 (95% CI: 1.48–8.71, 𝑝 = 0.0033)
and 2.86 (95% CI: 1.42–5.76, 𝑝 = 0.0028), respectively. In
the same study we found no significant association at all
between these two SNPs and tardive dyskinesia in 431 patients
with schizophrenia (𝑁 = 401, 95.1%) or schizotypical
disorders according to ICD-10 criteria. This might be related
to the specific genetic makeup of patients suffering from PD.
Schizophrenic patients do not have a genetically determined
vulnerability of dopaminergic neurotoxicity which is needed
to become specifically vulnerable to this NMDA effect.
4. Conclusions
We want to hypothesize that NMDA receptor related exci-
totoxicity plays an important role in both HD and LID. In
HD, excitotoxicity is caused by disinhibition of NR2B carry-
ing NMDA receptors which are more extensively stabilized
within the synaptic membrane and therefore are regularly
too active (become excitotoxic). In LID, we suggest that
the vulnerability to normal excitotoxic insults is potentiated
due to the contribution of increased intracellular oxidative
stress. This last phenomenon is expected to be caused by
the same genetic composition which is causing degeneration
of dopaminergic nigrostriatal neurons in these patients. As
medium spiny neurons of the indirect pathway are more
vulnerable to excitotoxicity than those of the direct pathway,
a mismatch between their activities is caused, which results
in instability and therefore an increased chance of adverse
reactions to stimulation of dopamine receptors.
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